Follicular dendritic cell sarcoma (FDCS) is a rare malignant neoplasm that can clinically mimic a number of other tumors. FDCS can follow either an indolent or aggressive course. The prognosis tends to be worse for patients with large or high-grade tumors and/or an intra-abdominal tumor site. For optimal management, complete surgical excision is recommended. Radiation therapy and/or chemotherapy may be considered for incompletely resected tumors and for tumors with poor prognostic features, but the exact role of adjuvant therapy is unknown. We report a case of cervical FDCS in a 39-year-old black man, and we review the presentation and management of this disorder, with emphasis on the differential diagnosis.
Introduction
Follicular dendritic cell sarcoma (FDCS) is a rare malignant neoplasm, with most cases involving lymph nodes. Its course can be indolent or locally aggressive. The natural history and response to different treatment modalities have not been fully defi ned. We report a case of FDCS of the neck, and we discuss the ongoing controversies in the diagnosis and management of this disease.
Case report
A 39-year-old black man presented with a 4-month history of an asymptomatic 3 × 4-cm left neck mass medial to the sternocleidomastoid muscle. He had initially been treated with antibiotics, but the size of the mass did not change. He denied fever, night sweats, weight loss, and dysphagia. He was a nonsmoker with no history of recent travel, tuberculosis exposure, or cat bites.
Laboratory studies revealed that his complete blood count, liver function, and immune status were within normal limits. Computed tomography (CT) revealed a left submandibular mass (fi gure 1); neither CT nor magnetic resonance imaging found any other associated abnormalities. The patient refused fi ne-needle aspiration.
The patient was taken for surgery, and a complete excision of the lesion was performed with negative surgical margins. Pathology revealed a neoplastic proliferation of spindle-shaped and oval cells and moderate to severe atypia with organization into whorls, fascicles, and storiform patterns. Many small lymphocytes within the tumor were noted on H&E staining (fi gure 2). Immunohistochemistry was positive for CD21 and CD23 (fi gure 3). These fi ndings were consistent with a diagnosis of FDCS.
Postoperatively, CT of the chest, abdomen, and pelvis detected no evidence of metastatic disease. However, follow-up positron-emission tomography of the neck performed 4 weeks postoperatively revealed enlarged, hypermetabolic lymph nodes in levels III and IV on the left side of the neck. Fine-needle aspiration cytology identifi ed persistent FDCS. A comprehensive left neck dissection was performed. Of 47 lymph nodes, 5 were positive for FDCS (level I: 0/1; level II: 1/17; level III: 2/4; level IV: 2/20; level V: 0/5). The patient then underwent intensity-modulated radiation therapy (IMRT) to a total www.entjournal.com ■ E15 dose of 6,480 cGy. Thereafter, the patient's compliance with follow-up examinations was poor, but he was doing well 24 months after the completion of IMRT, and he showed no evidence of recurrent disease.
Discussion
Follicular dendritic cell sarcoma is grouped with the histiocytic and dendritic cell neoplasms in the World Health Organization's classifi cation of tumors. Unfortunately, its natural history, management, and response to different treatment modalities are not fully defi ned because most of the available information on FDCS is based on case reports and small retrospective case series.
Follicular dendritic cells are nonlymphoid, nonphagocytic elements that fall under the generic designation accessory cells of the lymphoid system. Their primary role is to capture and present antigens and immune complexes. Follicular dendritic cells are primarily located in germinal centers; they have a dendritic confi guration, and they are occasionally multinucleated. 1,2 These cells have C3b and C3d complement receptors and HLA-DR on their surface. They are identifi ed by positive immunohistochemical staining for CD21 (C3d receptor), CD23, CD35 (C3b receptor), R4/23, Ki-M4, Ki-M4p, and Ki-FDC1p and ultrastructurally by the presence of long, interwoven cell processes connected by mature desmosomes. [3] [4] [5] The existence of a primary neoplasm of the lymph nodes that exhibits features of follicular dendritic cell differentiation was fi rst described by Lennert 6 in 1978, and the fi rst case report of follicular dendritic cell carcinoma was published by Monda et al 7 in 1986. FDCS typically occurs in young and middle-aged adults (mean age: 43 yr; range: 17 to 75); with no predilection for either sex. [8] [9] [10] It commonly presents as a painless, slowly progressive cervical lymphadenopathy. FDCS is most frequently found within the lymph nodes, but extranodal involvement has been seen in approximately 30% of cases; reported extranodal sites have included the liver, spleen, tonsil, palate, nasopharynx, pharynx, parapharyngeal space, thyroid, breast, and intra-abdominal soft tissue. [11] [12] [13] [14] [15] [16] In the head and neck, the area of the Waldeyer ring, and in particular the tonsils, is the most common location of extranodal presentation. 17 The etiology of FDCS is poorly understood. To date, the only predisposing factors that have been identifi ed are hyaline vascular Castleman disease and Epstein-Barr virus infection. A Castleman-disease-related lesion may be seen either before or concurrent with the development of FDCS. It has been proposed that FDCS arising in Castleman disease develops through a hyperplasiadysplasia-neoplasia sequence. However, it is also possible that the characteristic Castleman disease lesion is a reaction to FDCS rather than a precursor lesion. 18, 19 FDCS tumors are composed of spindle-shaped to oval cells with pale to eosinophilic cytoplasm, ill-defi ned cell outlines (creating a "syncytial" appearance), oval nuclei with bland clear or fi nely dispersed chromatin, and inconspicuous or small eosinophilic nucleoli. Characteristically, these tumor cells present in whorls, fascicles, sheets, and sometimes a storiform pattern. The neoplastic cells are intimately admixed with small lymphocytes, which show a prominent perivascular cuffi ng. Those tumors that demonstrate foci of necrosis, marked nuclear pleomorphism, abnormal mitoses, and high mitotic activity usually have an aggressive clinical behavior. 8 The differential diagnosis depends, in part, on the tumor location. It may include malignant melanoma, squamous cell carcinoma, interdigitating dendritic cell sarcoma, thymoma, malignant fi brous histiocytoma (storiform-pleomorphic type), synovial cell sarcoma, peripheral nerve sheath tumor, leiomyomatous tumor, and a variety of other mesenchymal lesions (table). 10 A diagnosis of FDCS can be confi rmed by immunohistochemistry and/or electron microscopy. The markers CD21 (C3d receptor), CD23, and CD35 (C3b receptor) are expressed by normal follicular dendritic cells and are present in most of the reported cases of FDCS. 8 For isolated head and neck FDCS, the local recurrence rate in a recent review was 38%, and the rate of distant metastasis was 15%; locoregional recurrence has been reported up to 15 years after initial treatment. 17 For FDCS at all anatomic sites, the recurrence rate and metastatic rate are similar-40 and 25%, respectively, with an overall mortality of 16%. 6 The prognosis tends to be worse for patients with large (≥5 cm) or high-grade tumors and/or an intra-abdominal tumor site. In addition, features such as a high mitotic count (≥5/10 HPF) and high-grade histology were associated with higher rates of recurrence and metastasis. 20 For optimal management, complete surgical excision is recommended. The exact role of adjuvant radiotherapy and/or chemotherapy is unknown. Multiple chemotherapeutic regimens have been used, including doxorubicin, cyclophosphamide, vincristine, and prednisone or ifosfamide, carboplatin, and epirubicin. 17, 21 Radiation therapy can be considered for incompletely resected tumors and tumors with poor prognostic features. 7 An approach to postoperative radiotherapy for head and neck FDCS similar to that used for treating carcinomas has been proposed, with irradiation to 6,000 to 7,000 cGy to the involved site and elective radiation to the uninvolved neck. 17 Soriano et al recently reported that patients treated with a combination of surgery, chemotherapy, and radiation had the longest diseasefree survival. 22 In conclusion, FDCS is a rare entity that can clinically mimic other tumors. Identifi cation of a distinct pattern of histopathologic features necessitates further analysis with immunohistochemical stains for follicular dendritic cells. A high level of suspicion is required in order to identify and treat this potentially aggressive tumor. Combined treatment with surgery and radiation, with the possible addition of a non-Hodgkin lymphoma-like chemotherapy regimen, may result in a better outcome, although this has not been fully established.
